Roche's lebrikizumab asthma trial posts results; new faricimab trial planned for eye disease
Roche reports terminated Phase III lebrikizumab adolescent asthma results and a new not-yet-recruiting faricimab trial in central serous chorioretinopathy.
This week brought a results posting for a long-closed Roche asthma study and a newly registered eye disease trial involving a Roche collaboration.
- Lebrikizumab, a Phase III trial in adolescents with uncontrolled asthma (NCT01875003), posted results on 2026-06-30. The study was terminated due to a sponsor decision to discontinue lebrikizumab development for the treatment of asthma1, after enrolling 346 participants (actual)1 and completing in December 2016.
- Faricimab, a Phase 2 trial for chronic central serous chorioretinopathy (NCT07681167), was first posted on 2026-07-02 and is sponsored by Singapore National Eye Centre with Hoffmann-La Roche as collaborator. The trial is not yet recruiting2 and plans to enroll 50 participants (estimated)2, with primary completion estimated for August 2029.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.